Search
Neuronetics Inc
STIMAdd to Watchlist
1.410USD
+0.060+4.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
98.11MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.44%
5 Days
+11.02%
1 Month
-9.62%
6 Months
-2.08%
Year to Date
+2.17%
1 Year
-58.77%
Key Figures
1.370Open
1.410High
617.61KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.89%Turnover Ratio
1.350Prev. Close
1.335Low
604.24KTurnover
LossP/E Static
7.40P/B
0.00%Div Yield TTM
-27.84%ROA
4.84952wk High
0.61Volume Ratio
-43.71MNet Profit
69.58MShares
-0.5402EPS TTM
1.07Beta
-152.36%ROE
0.80052wk Low
5.56%Amplitude
46.89%Gross Margin
98.11MMarket Cap
-0.47Reward/Risk
6.11%Risk Rate
TradingKey Stock Score of Neuronetics Inc
Currency: USD Updated: 2026-07-01Key Insights
Neuronetics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 93 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.33.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuronetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neuronetics Inc Highlights
StrengthsRisks
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.06% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 149.16M.
Fairly Valued
The company’s latest PE is -2.50, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.87M shares, decreasing 13.05% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 5.49K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.02.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
4.333
Target Price
+218.63%
Upside Space
Neuronetics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neuronetics Inc Info
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Ticker SymbolSTIM
CompanyNeuronetics Inc
CEOMr. Keith J. Sullivan
Websitehttps://neurostar.com/neuronetics/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
53071.700
+229.200 (+0.43%)
29427.700
+116.300 (+0.40%)
7499.100
+27.600 (+0.37%)
14812.000
+9.000 (+0.06%)
69011.000
+863.000 (+1.27%)
6371.400
+18.600 (+0.29%)
68.373
+0.029 (+0.04%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4186.320
+64.410 (+1.56%)
FAQs
What is the current price of Neuronetics Inc (STIM)?
The current price of Neuronetics Inc (STIM) is 1.41.
What is the symbol of Neuronetics Inc?
The ticker symbol of Neuronetics Inc is STIM.
What is the 52-week high of Neuronetics Inc?
The 52-week high of Neuronetics Inc is 4.85.
What is the 52-week low of Neuronetics Inc?
The 52-week low of Neuronetics Inc is 0.80.
What is the market capitalization of Neuronetics Inc?
The market capitalization of Neuronetics Inc is 98.11M.
Is Neuronetics Inc (STIM) currently rated as Buy, Hold, or Sell?
According to analysts, Neuronetics Inc (STIM) has an overall rating of Buy, with a price target of 4.33.
What is the Earnings Per Share (EPS TTM) of Neuronetics Inc (STIM)?
The Earnings Per Share (EPS TTM) of Neuronetics Inc (STIM) is -0.59.